|
Update Series (2015) Lesson 32: Functional Outcomes and Complications following Transurethral Procedures for Benign Prostatic Obstruction Relief |
|
|
|
$0.00 |
For the most timely topics and latest surgical techniques in urology, you won’t want to miss the 2015 AUA Update Series—the AUA’s most popular self-study CME product.All new topics for 2015! |
|
Live from AUA2023: Highlights in BPH |
|
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation
|
|
$0.00 |
Live from AUA2023: Highlights in BPH is a panel discussion filmed during the 2023 AUA Annual Meeting!This activity is designed to increase the urologist’s understanding of how to translate the latest scientific advances into their routine clinical practice, improving the care of patients with BPH. |
|
Update Series (2015) Lesson 38: Evaluation and Management of Nocturia |
|
|
|
$0.00 |
For the most timely topics and latest surgical techniques in urology, you won’t want to miss the 2015 AUA Update Series—the AUA’s most popular self-study CME product.All new topics for 2015! |
|
Contemporary Pharmacotherapy for OAB 2023: Monotherapy and Combined Pharmacotherapy to Optimize Treatment Webcast (2023) |
|
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation
|
|
$0.00 |
Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation and innovation. |
|
Refractory Overactive Bladder: How to Select 3rd Line Therapies and Optimize Outcomes Webcast (2023) |
|
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation
|
|
$0.00 |
Upon completion, participants will be familiar with third-line therapies available to treat refractory overactive bladder (OAB), including the pros and cons of each option, the current data regarding outcomes to facilitate proper patient counseling and optimal techniques to maximize the success of the various therapies. The case-based format will provide real-world scenarios by which to learn about the implementation of successful third-line options. |
|
The Changing Face of Advanced Prostate Cancer Webcast (2023) |
|
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation
|
|
$0.00 |
This is an ongoing course on advanced prostate cancer at the AUA Annual Meeting since 2012, and the changes over the last decade have been nothing less than breathtaking! In the early years, it was all about metastatic castrate-resistant prostate cancer (CRPC) with multiple new therapeutic advances starting in 2010, followed by abiraterone and enzalutamide and a focus on bone-targeted agents. |
|
Update Series (2021): Test Your Knowledge Lessons 16-20 |
|
|
|
$0.00 |
For our annual subscribers, we are excited to continue to offer a new feature to the Update Series! If you like to answer questions to help you study and learn, we are now offering Test Your Knowledge activities with each release of the Update Series.This new feature: |
|
AUA Guidelines on Advanced Prostate Cancer Webcast (2023) |
|
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation
|
|
$0.00 |
Incorporating the most updated AUA/ASTRO/SUO APC Guidelines, this course will be comprehensive in the approach to the diagnosis, management and outcomes of men with advanced, metastatic hormone sensitive prostate cancer (mHSPC) and castration-resistant prostate cancer (CRPC). The course will include germline testing, PSMA positron emission tomography imaging, and the use of androgen deprivation therapy in combination with novel androgen axis therapy and chemotherapy in men with newly diagnosed metastatic hormone-sensitive prostate cancer. |
|
Update Series (2021): Test Your Knowledge 36-40 |
|
|
|
$0.00 |
For our annual subscribers, we are excited to continue to offer a new feature to the Update Series! If you like to answer questions to help you study and learn, we are now offering Test Your Knowledge activities with each release of the Update Series.This new feature: |
|
Prostate Cancer Diagnosis: AUA Guidelines on Use of PSA Biomarkers, MRI and Biopsy Techniques Webcast (2023) |
|
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation
|
|
$0.00 |
Prostate cancer detection remains one of the most common and most controversial aspects of urological practice. In addition to the complexities around screening and use of PSA, the role of other biomarkers, biopsy techniques such as transperineal biopsy and MRI for targeted biopsy are evolving rapidly. This course is intended for urologists, advanced practice providers and trainees interested in using the most evidence-based methods for optimizing detection of clinically important prostate cancers, while improving patient experience and minimizing complications. |
|
Update Series (2022): Test Your Knowledge Lessons 6-10 |
|
|
|
$0.00 |
For our annual subscribers, we are excited to continue to offer a new feature to the Update Series! If you like to answer questions to help you study and learn, we are now offering Test Your Knowledge activities with each release of the Update Series.The Test Your Knowledge activity: |
|
Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider Webcast (2023) |
|
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation
|
|
$0.00 |
Review of advanced and metastatic prostate, bladder and kidney cancer. Most recent treatment guidelines are reviewed along with the studies that support them. Different disease spaces in oncologic care are discussed, including the medications used to treat them, their mechanism, side effects and efficacy. Role of the advanced practice provider is discussed for each tumor type. Finally, cases are presented along with management options for audience participationACKNOWLEDGEMENTSIndependent educational grant support provided by: |
|
Update Series (2016) Lesson 10: Initial Evaluation and Management of Acute Urinary Retention |
|
|
|
$0.00 |
For the most timely topics and latest surgical techniques in urology, you won't want to miss the 2016 AUA Update Series—AUA's most popular self-study CME product.Concise, practical lessons on timely topicsState-of-the-art surgical techniquesAuthors are among the best in their specialtiesEarn up to 40 AMA PRA Category 1 Credits™ |
|
Update Series (2022): Test Your Knowledge Lessons 16-20 |
|
|
|
$0.00 |
For our annual subscribers, we are excited to continue to offer a new feature to the Update Series! If you like to answer questions to help you study and learn, we are now offering Test Your Knowledge activities with each release of the Update Series.The Test Your Knowledge activity: |
|
How to use PSMA-PET/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent Webcast (2023) |
|
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation
|
|
$0.00 |
he learners will understand the following critical clinical aspects with regard to the clinical application of prostate-specific membrane antigen (PSMA)-positron emission tomography (PET)/CT scanning mode of action of PSMA-PET/CT: pitfalls of PSMA-PET/CT diagnostic accuracy depending on PSA, PSA double time, prostate cancer histology, application of PSMA-PET/CT to identify patients with intrapelvic nodal relapse who will benefit from local therapy such as salvage lymphadenectomy or stereotactic radiation therapy, application of PSMA-PET/CT to identify patients with organ-confined radiorecur |
Facebook
Twitter
LinkedIn
Forward